Summary

In chronic lymphocytic leukemia, progression-free survival in minimal residual disease–negative patients can be best predicted using a combination of minimal residual disease and the clinical response. The combination is more accurate than clinical response alone. Assessment using only splenomegaly has no influence on progression-free survival prediction.